We are live on
!
Find out more
SFCM
Seven Fleet Capital Management Portfolio holdings
AUM
$318M
This Fund
S&P 500
This Quarter
Est. Return
+43.96%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$148M
AUM Growth
–
Cap. Flow
+$138M
Cap. Flow
% of AUM
93.63%
Top 10 Holdings %
Top 10 Hldgs %
68.44%
Holding
85
New
85
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$62.7M |
| 2 |
SLNO
Soleno Therapeutics
SLNO
|
+$7.13M |
| 3 |
Cogent Biosciences
COGT
|
+$6.02M |
| 4 |
Revolution Medicines
RVMD
|
+$4.31M |
| 5 |
TERN
Terns Pharmaceuticals
TERN
|
+$3.01M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$6.35B
| $62.9M | 42.57% |
+1,515,151
| New | +$62.7M |
|
|
2
Cogent Biosciences
COGT
$6.8B
| $7.6M | 5.15% |
+214,099
| New | +$6.02M |
|
|
SLNO
3
DELISTED
Soleno Therapeutics
SLNO
| $6.02M | 4.08% |
+130,079
| New | +$7.13M |
|
|
TERN
4
DELISTED
Terns Pharmaceuticals
TERN
| $5.27M | 3.57% |
+130,413
| New | +$3.01M |
|
|
5
Revolution Medicines
RVMD
$38.7B
| $5.24M | 3.55% |
+65,800
| New | +$4.31M |
|
6
Liquidia Corp
LQDA
$7.52B
| $3.15M | 2.13% |
+91,267
| New | +$2.6M |
|
7
Compass Therapeutics
CMPX
$364M
| $3.05M | 2.07% |
+568,747
| New | +$2.63M |
|
8
Exelixis
EXEL
$14.1B
| $3.01M | 2.03% |
+68,569
| New | +$2.84M |
|
9
Assembly Biosciences
ASMB
$506M
| $2.51M | 1.7% |
+73,762
| New | +$2.38M |
|
10
Axsome Therapeutics
AXSM
$12B
| $2.37M | 1.6% |
+12,955
| New | +$1.81M |
|
11
Tyra Biosciences
TYRA
$1.83B
| $2.09M | 1.42% |
+79,560
| New | +$1.46M |
|
12
Tango Therapeutics
TNGX
$4.3B
| $1.91M | 1.29% |
+215,172
| New | +$1.85M |
|
|
ABVX
13
Abivax
ABVX
$10.8B
| $1.82M | 1.23% |
+13,499
| New | +$1.47M |
|
14
Xencor
XNCR
$1.45B
| $1.68M | 1.14% |
+109,554
| New | +$1.64M |
|
15
Enliven Therapeutics
ELVN
$3.8B
| $1.54M | 1.04% |
+99,953
| New | +$1.99M |
|
16
Pharvaris
PHVS
$2.34B
| $1.54M | 1.04% |
+55,342
| New | +$1.33M |
|
17
Mineralys Therapeutics
MLYS
$2.35B
| $1.53M | 1.03% |
+42,025
| New | +$1.69M |
|
|
BLTE
18
Belite Bio
BLTE
$6.21B
| $1.47M | 0.99% |
+9,161
| New | +$1.09M |
|
19
Dyne Therapeutics
DYN
$4.26B
| $1.37M | 0.93% |
+70,180
| New | +$1.33M |
|
|
NUVL
20
DELISTED
Nuvalent
NUVL
| $1.27M | 0.86% |
+12,601
| New | +$1.24M |
|
21
Ascendis Pharma A/S
ASND
$16.3B
| $1.21M | 0.82% |
+5,670
| New | +$1.17M |
|
|
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
| $1.17M | 0.8% |
+82,500
| New | +$810K |
|
23
Vaxcyte
PCVX
$8B
| $1.17M | 0.79% |
+25,365
| New | +$1.13M |
|
24
Avalo Therapeutics
AVTX
$1.02B
| $1.15M | 0.78% |
+63,343
| New | +$1.07M |
|
25
Inhibikase Therapeutics
IKT
$361M
| $1.09M | 0.74% |
+533,648
| New | +$849K |
|
Similar funds
EFN
CC
WIS
JWM
SA
TM
BWS
GWP
Seven Fleet Capital Management's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Seven Fleet Capital Management, which disclosed 85 positions worth $148M. Its ten largest holdings account for 68% of the portfolio.
Its largest position is CG Oncology: 1,515,151 shares worth $62.9M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Seven Fleet Capital Management's largest Q4 2025 buy was CG Oncology: 1,515,151 shares worth $62.9M.
- Seven Fleet Capital Management's ten largest holdings make up 68% of its $148M portfolio in Q4 2025.
- Seven Fleet Capital Management disclosed 85 positions in Q4 2025, its first 13F filing on record.
Based on Seven Fleet Capital Management's 13F filing for Q4 2025, filed 26 Feb 2026.